Silpa-archa Sukhum, Lee Joan J, Foster C Stephen
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA Ocular Immunology & Uveitis Foundation, Cambridge, Massachusetts, USA Faculty of Medicine, Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA Ocular Immunology & Uveitis Foundation, Cambridge, Massachusetts, USA.
Br J Ophthalmol. 2016 Jan;100(1):135-41. doi: 10.1136/bjophthalmol-2015-306629. Epub 2015 Apr 22.
Systemic lupus erythematosus (SLE) can involve many parts of the eye, including the eyelid, ocular adnexa, sclera, cornea, uvea, retina and optic nerve. Ocular manifestations of SLE are common and may lead to permanent blindness from the underlying disease or therapeutic side effects. Keratoconjunctivitis sicca is the most common manifestation. However, vision loss may result from involvement of the retina, choroid and optic nerve. Ocular symptoms are correlated to systemic disease activity and can present as an initial manifestation of SLE. The established treatment includes prompt systemic corticosteroids, steroid-sparing immunosuppressive drugs and biological agents. Local ocular therapies are options with promising efficacy. The early recognition of disease and treatment provides reduction of visual morbidity and mortality.
系统性红斑狼疮（SLE）可累及眼部的许多部位，包括眼睑、眼附属器、巩膜、角膜、葡萄膜、视网膜和视神经。SLE的眼部表现很常见，可能会因潜在疾病或治疗副作用导致永久性失明。干燥性角结膜炎是最常见的表现。然而，视网膜、脉络膜和视神经受累可能导致视力丧失。眼部症状与全身疾病活动相关，可作为SLE的首发表现。既定的治疗方法包括及时使用全身性皮质类固醇、糖皮质激素节省免疫抑制药物和生物制剂。局部眼部治疗是疗效有望的选择。疾病的早期识别和治疗可降低视觉发病率和死亡率。
